Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report Intel FAQ API Sign In →
31 /100
MEDIUM RISK
Score updated Jul 28, 2026

ARCT — Arcturus Therapeutics Holdings Inc. Dilution Risk Tracker

Track ARCT dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track ARCT — Get alerts when the score changes →

As of July 28, 2026, Arcturus Therapeutics Holdings Inc. (ARCT) has a DilutionWatch DilutionScore of 31/100, rated MEDIUM dilution risk. Arcturus Therapeutics Holdings Inc. has a market capitalization of $225.11M, 28.42M shares outstanding, 127 institutional holders tracked. Key dilution vectors include approximately 26 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

Score Breakdown

📋 Offering Ability
40
💰 Cash Runway
10
📊 Float Risk
20
⚠️ Warrant Exposure
40
🔄Convertible Debt

Dilution Forecast

☀️
Clear
No significant dilution signals
0%
No significant dilution signals detected for ARCT.
🔔 Track ARCT — Get forecast alerts →

Market Data

Market Cap$225.11M
Shares Outstanding28.42M
Float26.15M
Cash$211.38M
Debt$75.66M
Short InterestN/A

Institutional Holdings

QoQ: ↑ 14.4% shares (2026Q1 vs prior)
127 institutional holders · 28.54M shares
#1 FEDERATED HERMES, INC. 3.30M shares
#2 ARK Investment Management LLC 2.77M shares
#3 BlackRock, Inc. 2.61M shares
+ 17 more holders Sign up free to view →

Short Interest

Short Interest7.00M
Days to Cover10.7
% of Float26.8%
FINRA data as of Jul 15, 2026

Recent SEC Activity

No recent SEC insights

Recent News

No recent news

What This Means for ARCT Shareholders

Arcturus Therapeutics Holdings Inc. (ARCT) has a DilutionScore of 31/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 28, 2026.

DilutionWatch's EDGAR monitoring for ARCT shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for ARCT in real-time, scanning EDGAR every 60 seconds. The DilutionWatch shows real-time score changes for ARCT alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.

Understanding ARCT's Dilution Risk Factors

Primary Risk Drivers

The most significant dilution risks for Arcturus Therapeutics Holdings Inc. stem from Offering Ability and Cash Runway scores. Offering Ability is currently at a moderate level, indicating the company has the capacity to raise capital through equity offerings, which can lead to share issuance and dilution of existing ownership. The Cash Runway score of 10 reflects that while the company has a solid financial buffer, it is not excessively deep, meaning any substantial funding needs could quickly deplete reserves and necessitate further capital raises.

Factors Currently Not a Concern

Float Risk and Warrant Exposure are currently low, suggesting minimal immediate dilution from these sources. Float Risk at 20 indicates that the company’s share distribution is not heavily concentrated among a small group of investors, reducing potential manipulation risks. Warrant Exposure at 40 shows that while warrants exist, their impact on total shares outstanding remains manageable. A change in either area would become concerning if new warrants were issued or if the float became significantly reduced through large-scale trading activity.

SEC Filings to Watch

Key filings to monitor include S-3 registration statements, which signal potential future equity offerings; 424B5 documents, often used for shelf registrations that allow rapid capital raising; and 8-K Item 1.01, indicating new events such as the initiation of financing activities. Additionally, 10-Q reports should be reviewed for changes in cash position or any mention of planned financings. These filings provide early signals about upcoming share issuance or financial stress that could affect dilution levels.

How Dilution Happens

When a company raises capital through equity offerings, it issues new shares to investors. This directly increases the total number of shares outstanding, thereby reducing the ownership percentage of existing shareholders. For ARCT, if Offering Ability is leveraged and the company needs additional funds, it could issue new stock at a discount or through rights offerings, diluting current holders. The Cash Runway score indicates that while there’s no immediate cash crunch, if this buffer were to shrink, the company may be forced to seek funding via equity issuance, increasing share count.

What Would Make This Worse

If ARCT were to initiate a large-scale equity offering or issue convertible notes that convert into shares at below-market prices, the dilution impact would intensify. Additionally, if the company’s cash runway shrinks significantly and it must raise funds urgently, it could resort to issuing warrants or rights issues at discounted rates, further increasing share count. Any major financial distress leading to a need for emergency capital could escalate these risks and lead to a substantial dilution event.

Key Insight

Despite moderate Offering Ability and low Cash Runway scores, ARCT’s current financial buffer allows time for strategic capital raising without immediate dilution pressure.

How to Monitor ARCT for Dilution Risk

What This Risk Level Means

For an operating company in the micro-cap space like Arcturus Therapeutics Holdings Inc., a medium dilution risk score indicates that while the company is not currently under extreme pressure, it has notable exposure to potential dilution events. Micro-cap companies often rely on capital raises to fund operations and growth, making them more susceptible to dilutive actions such as equity offerings or convertible debt conversions. A score in this range suggests that while there’s no immediate crisis, the company's financial flexibility is constrained by ongoing or potential issuance of new securities.

What Typically Happens Next

Companies with a medium dilution risk profile often proceed through staged capital raising efforts, including shelf registrations and ATM programs, which allow for flexible fundraising over time. Warrant exercises are also common in this space, particularly when companies seek to incentivize investors or reduce debt. Convertible notes may be converted into equity at maturity, further increasing the potential for dilution. These actions typically unfold over 6–12 months, and monitoring their timing is critical for assessing risk escalation.

Monitoring Playbook

To track ARCT effectively, use DilutionWatch to regularly check score changes, particularly in Offering Ability, Warrant Exposure, and Convertible Note Risk. Set alerts for any factor reaching 40 or above, and monitor filings quarterly. Watch for announcements of new offerings or warrant exercises, and track the company’s cash runway, which can be found in SEC reports. When thresholds are triggered, review recent SEC documents like Form S-1 or S-3 for pending offerings. Shelf & ATM Monitor is also valuable for tracking upcoming capital activity.

Early Warning Signals

Several specific signals indicate worsening dilution risk: a sudden spike in Offering Ability or Warrant Exposure scores to 40 or higher, a filing for a new shelf registration or ATM program, and an increase in the number of outstanding warrants nearing exercise. These changes often occur before actual dilutive events and should prompt immediate review of company financials and recent SEC filings.

What a Positive Resolution Looks Like

A positive resolution would involve a capital raise that significantly improves cash reserves, reducing reliance on future equity issuance. Paying down convertible debt or allowing warrants to expire without exercise also helps reduce dilution risk. If the company demonstrates improved financial stability and reduces exposure in key dilutive factors — such as lowering Offering Ability or Convertible Note Risk scores — it would signal a healthier capital structure and decreased risk of further dilution.

Watch For

Any new SEC filings related to equity offerings, warrant exercises, or convertible note conversions that could signal an increase in dilution exposure.

Full SEC filing analysis available with free account  →
Track ARCT Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking ARCT — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for ARCT
ARCT FDA Catalyst Timeline & Biotech Grade — BiotechSignsARCT Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.